BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28501328)

  • 1. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Cohen JG; Prendergast E; Geddings JE; Walts AE; Agadjanian H; Hisada Y; Karlan BY; Mackman N; Walsh CS
    Gynecol Oncol; 2017 Jul; 146(1):146-152. PubMed ID: 28501328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
    Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
    Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
    Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
    Diaz ES; Walts AE; Karlan BY; Walsh CS
    Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism.
    Sakurai M; Matsumoto K; Gosho M; Sakata A; Hosokawa Y; Tenjimbayashi Y; Katoh T; Shikama A; Komiya H; Michikami H; Tasaka N; Akiyama-Abe A; Nakao S; Ochi H; Onuki M; Minaguchi T; Yoshikawa H; Satoh T
    Int J Gynecol Cancer; 2017 Jan; 27(1):37-43. PubMed ID: 27755234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
    Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
    Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.
    Claussen C; Rausch AV; Lezius S; Amirkhosravi A; Davila M; Francis JL; Hisada YM; Mackman N; Bokemeyer C; Schmalfeldt B; Mahner S; Langer F
    Thromb Res; 2016 May; 141():39-48. PubMed ID: 26967531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.
    Uno K; Homma S; Satoh T; Nakanishi K; Abe D; Matsumoto K; Oki A; Tsunoda H; Yamaguchi I; Nagasawa T; Yoshikawa H; Aonuma K
    Br J Cancer; 2007 Jan; 96(2):290-5. PubMed ID: 17211468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.
    Ma Z; Zhang T; Wang R; Cheng Z; Xu H; Li W; Wang Y; Wang X
    Int J Gynecol Cancer; 2011 May; 21(4):616-24. PubMed ID: 21543928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
    Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
    Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
    Kumar A; Hurtt CC; Cliby WA; Martin JR; Weaver AL; McGree ME; Langstraat CL; Bakkum-Gamez JN
    Gynecol Oncol; 2017 Dec; 147(3):514-520. PubMed ID: 28947173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue factor expression and tumor-infiltrating T lymphocytes in ovarian carcinomas and their association with venous thromboembolism.
    Gi T; Yamashita A; Aman M; Kuwahara A; Asada Y; Kawagoe Y; Onishi J; Sameshima H; Sato Y
    Pathol Int; 2021 Apr; 71(4):261-266. PubMed ID: 33559251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
    Chanakira A; Westmark PR; Ong IM; Sheehan JP
    Gynecol Oncol; 2017 Apr; 145(1):167-175. PubMed ID: 28148395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients.
    Thaler J; Preusser M; Ay C; Kaider A; Marosi C; Zielinski C; Pabinger I; Hainfellner JA
    Thromb Res; 2013 Feb; 131(2):162-5. PubMed ID: 23084660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
    Han LY; Landen CN; Kamat AA; Lopez A; Bender DP; Mueller P; Schmandt R; Gershenson DM; Sood AK
    J Clin Oncol; 2006 Feb; 24(5):755-61. PubMed ID: 16380413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition.
    Ose J; Fortner RT; Rinaldi S; Schock H; Overvad K; Tjonneland A; Hansen L; Dossus L; Fournier A; Baglietto L; Romieu I; Kuhn E; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Masala G; Sieri S; Tumino R; Sacerdote C; Mattiello A; Ramon Quiros J; Obón-Santacana M; Larrañaga N; Chirlaque MD; Sánchez MJ; Barricarte A; Peeters PH; Bueno-de-Mesquita HB; Onland-Moret NC; Brändstedt J; Lundin E; Idahl A; Weiderpass E; Gram IT; Lund E; Kaw KT; Travis RC; Merritt MA; Gunther MJ; Riboli E; Kaaks R
    Int J Cancer; 2015 Jan; 136(2):399-410. PubMed ID: 24890047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?
    Tesselaar ME; Romijn FP; Van Der Linden IK; Prins FA; Bertina RM; Osanto S
    J Thromb Haemost; 2007 Mar; 5(3):520-7. PubMed ID: 17166244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.
    Matsuo K; Yoshino K; Hasegawa K; Murakami R; Ikeda Y; Adachi S; Hiramatsu K; Yokoyama T; Nishimura M; Sheridan TB; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Fotopoulou C; Roman LD; Sood AK
    Gynecol Oncol; 2015 Feb; 136(2):198-204. PubMed ID: 25497604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.